News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Affymetrix (Santa Clara, California) (AFFX) And Vita Genomics Inc. Collaborate To Develop Microarray-Based IVD Products



12/27/2005 11:43:59 AM

SANTA CLARA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Dec. 26, 2005--Affymetrix Inc. (Nasdaq: AFFX) and Vita Genomics announced today that Affymetrix has granted Vita Genomics and its fully owned subsidiary, Shanghai GeneCore BioTechnologies, non-exclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests for Alpha Interferon Treatment response in patients with HBV and HCV, as well as for early onset and allergic asthma in infants and young children. The resulting microarray-based IVD products would provide clinicians with better diagnosis methods and more efficient approaches for treating patients and managing these diseases. As part of the Powered by Affymetrix(TM) program, Vita Genomics is able to incorporate Affymetrix' patented arrays into its molecular diagnostic assays developed to predict drug efficacy prior to treatment and assess risks to facilitate disease prevention.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES